

1 **Minutes of the DPTC Teleconference**
2 **on 2 August 2006**

3 **ATTENDEES**

4 Terry Tougas, *Chair* (Boehringer Ingelheim, IPAC-RS)
5 David Christopher (Schering-Plough, IPAC-RS)
6 Bob Dana (PDA)
7 Sylvia Gantt (PQRI Exec. Secretary)
8 Michael Golden (GlaxoSmithKline, IPAC-RS)
9 Frank Holcombe (FDA)
10 Lana Lyapustina (IPAC-RS Secretariat)
11 Dan Malinowski (Pfizer, PhRMA)
12 Chris Moreton (Idenix Pharmaceuticals, IPEC)
13 Lee Nagao (IPAC-RS Secretariat)
14 Raj Uppoor (FDA)
15 Bob Wiens (Lilly, IPEC)

16 ***Absentees***

17 Tony Amann (GPhA)
18 Clyde Anthony (USP)
19 Dan Norwood (Boehringer Ingelheim, IPAC-RS)
20 Rich Poska (Abbot, PhRMA)
21 Nakissa Sadrieh (FDA)
22 Vilayat Sayeed (FDA)
23 Robert Seevers (Lilly, PhRMA)
24 Russel Somma (IPS, ISPE)
25 Bill Williams (University of Texas, AAPS)
26 Bruce Wyka (Schering-Plough, IPAC-RS)

27 **EXECUTIVE SUMMARY**

- 28 • The L&E working group should present to the DPTC a plan for publications that would
29 constitute the 'roll-out' of the Recommendations.
- 30 • The proposal for L&E book publishing should be revised and resubmitted as a new work
31 project proposal.
- 32 • The revised portions of the L&E Recommendations and the Working Group's responses to
33 all comments should be reviewed by the DPTC over the next four weeks.
- 34 • The DPTC comments on the protocol prepared by the Container Closure Working Group
35 should be submitted by end of business on Monday, 7 August.
- 36 • The Profile Comparisons Working Group's Final Report will be completed by the end of
37 August and submitted to DPTC for review in September. The Working Group will also be

38 reviewing comments from the journal on its Interim Report submitted for publication earlier
39 this year.

- 40 • The submission of the Mass Balance technical paper is expected in September. It will
41 complete the Working Group's activities.
- 42 • The Stability Proposal is a proposal to establish a PQRI working group on this topic, rather
43 than a detailed report on the issue. Many of the comments raised by the Steering Committee
44 could be addressed by the working group, once it is approved and formed.

45 **DISCUSSION**

46 *Opening*

47 Dr. Tougas opened the meeting and read the antitrust admonition: "Our discussions today are
48 subject to the anti-trust guidance applicable in the U.S. and E.U. Nothing discussed at this
49 meeting is intended to restrict the individual decision-making of any member company or to
50 represent an agreement to coordinate marketing or sales conduct. Those participating in this
51 meeting are instructed to avoid discussion of competitively sensitive subjects, including, but
52 not limited to, confidential marketing, sales, and pricing information."

53 The proposed objectives of the meeting were to discuss updates on all Working Groups and
54 the SC comments on the Stability Proposals.

55 *Leachables and Extractables*

56 Dr. Nagao reported that the L&E Working Group has completed revising the
57 Recommendations and Responses to Comments. Both documents are ready for the DPTC
58 review. The Committee agreed that four weeks should be sufficient for review, and that the
59 current review should focus on the changes to the Recommendations, not on the entire
60 document.

61 Dr. Nagao further reported that the faculty of the L&E Training Course held a meeting
62 recently to discuss the program and expectations. She explained that the focus will be on
63 interactive teaching and not only on podium presentations. To date, 38 individuals registered
64 for the course. The reserved room holds a maximum of 70. The DPTC viewed this as an
65 indication of strong interest in the course and congratulated the Working Group. Further
66 information about the course is posted at
67 http://pqri.org/workshops/leach_ext/pqrilandeshop.asp.

68 Dr. Nagao explained that the Working Group is planning to prepare two publications based
69 on its Recommendations. One article would be based on the presentations made at the March
70 Society of Toxicology meeting, and is targeted for the Toxicological Sciences journal, which
71 is well regarded in the toxicological community. The article would provide a background on
72 the development and use of the safety threshold and would have a short section on how it
73 relates to chemistry.

74 The second publication would be an article or a series of articles on best practices for L&E,
75 possibly as a themed issue of a journal (although the journal has not been selected yet). This
76 series of papers would address the different portions of the L&E Recommendations, but at a
77 more detailed level. The goal is to present and highlight the data that underpins the
78 Recommendations. Special chapters/articles would be devoted to the Safety Threshold and
79 the Analytical Evaluation Threshold.

80 Ms. Gantt reported that the Wiley publishers contract for an L&E book is being reviewed by
81 an AAPS attorney, who would be providing her comments shortly.

82 The participants discussed the new work proposal (“Education Working Group”) submitted
83 by the L&E Working Group to the DPTC for comment. Dr. Tougas and others clarified that
84 the publications intended as aid in the ‘roll-out’ of the L&E Recommendations are well
85 within the original Work Plan and should be completed by the current L&E Working Group.
86 The book publishing, on the other hand, would be handled by a smaller number of key people
87 and should be considered a new work item. The L&E Working Group should therefore
88 revise its proposal accordingly and to resubmit it to the DPTC along with a plan for all
89 publications (e.g., what will be published, where and why).

90 *Container Closure System*

91 Mr. Malinowski highlighted two CVs for candidates proposed for this Working Group.

92 He further explained that the Working Group would be meeting next week to finalize its
93 protocol for screening experiments and requested the DPTC comments by the end of
94 business on Monday, 7 August. Mr. Malinowski provided a brief overview of the protocol
95 that had been circulated to the DPTC by email.

96 Dr. Uppoor asked why the ICH conditions were not used, and Mr. Malinowski explained that
97 for the screening study, only room/ambient USP and accelerated conditions were proposed to
98 establish a baseline. In the subsequent larger study the complete ICH conditions (which are
99 more relevant to manufacturers) would be used.

100 Dr. Uppoor further proposed that the sink capacity of the dessicant be studied through use of
101 opened bottles with 30 g dessicant. Dr. Moreton and Mr. Malinowski explained that the
102 amount of dessicant had been chosen based on existing tables and data pertaining to
103 dessicant’s sink capacity. They assured Dr. Uppoor that this data would be available for the
104 final study.

105 The DPTC members agreed to provide further comments in writing by 7 August.

106 *Profile Comparisons*

107 Mr. Christopher reported that comments on the Working Group’s Interim Report have been
108 received and would be discussed by the Working Group shortly. In parallel, the Working
109 Group is completing its Final Report, which should be available for the DPTC review in
110 September.

111 ***Excipients***

112 Mr. Wiens reported that the Working Group's article has been accepted for publication in the
113 *Pharmaceutical Technology*, and should be appearing in the September issue. The DPTC
114 congratulated the Working Group on this success. Mr. Wiens thanked the PQRI for support.

115 Mr. Wiens further reported that preparations for the upcoming Workshop
116 (<http://pqri.org/workshops/Excipient/Excipient06.asp>) are under way, all scribes and
117 moderators have been recruited and registration is ongoing. FDA is represented on the
118 committee by Dr. Raj Uppoor and Dr. Barry Rothman. There will be two FDA speakers at
119 the Workshop, who will review current regulations on excipients control.

120 Mr. Golden asked whether novel excipients would be addressed. Mr. Wiens and Dr. Uppoor
121 explained that these are outside the current scope of the Workshop, which is built around
122 results the survey conducted by the Working Group and the identified issues. Dr. Moreton
123 noted that clinical/safety aspects of novel excipients are addressed in an FDA guidance, and
124 CMC issues are being addressed by IPEC-America.

125 ***Mass Balance***

126 Dr. Tougas reported that final minor changes are being added to the mass balance technical
127 paper, which is scheduled to be submitted to the Journal of Aerosol Medicine in September.

128 ***Stability Proposal***

129 Dr. Tougas reported on the comments received from the Steering Committee in response to
130 the Stability Proposal. He said responses to date are supportive of this project going forward,
131 are positive, although there were some comments submitted that seem to be based on a
132 misunderstanding. Discussions with the relevant organizations and individuals are ongoing.

133 Dr. Tougas also noted that many of the comments submitted by the Steering Committee are
134 of technical nature, and should have been brought up and addressed at the Technical
135 Committee level. Dr. Tougas is discussing these process deficiencies with the SC Chair.

136 Dr. Uppoor said that the proposal is lacking the pharmaceutical scientist's perspective. Dr.
137 Holcombe and Dr. Tougas explained that the details of the proposed work could be further
138 developed and elaborated upon by the experts on the Working Group once it is formed. The
139 current proposal is a general proposal to start work and examine these issues. Being only a
140 proposal for work, the document could not examine and present all details at this stage.

141 **NEXT MEETING/TELECONFERENCE**

142 The next DPTC teleconference is scheduled for 23 October, Monday, at 10:00 AM ET .

143

Finalized on 31 August 2006